Suppr超能文献

评估 32 项运动功能测量在 2 型或非卧床 3 型脊髓性肌萎缩症患者中的有效性和可靠性。

Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy.

机构信息

Roche Products Limited, Welwyn, United Kingdom.

Department of Pediatric Physical Medicine and Rehabilitation, Hôpital Mère Enfant, CHU-Lyon, Lyon University, Lyon, France.

出版信息

PLoS One. 2020 Sep 18;15(9):e0238786. doi: 10.1371/journal.pone.0238786. eCollection 2020.

Abstract

The 32-item Motor Function Measure (MFM32) is an assessment of motor function, and its measurement properties were established in a broad neuromuscular disease population. This study sought to investigate the reliability, validity, and ability to detect change of MFM32 in individuals with Type 2 and non-ambulant Type 3 spinal muscular atrophy (SMA). Data were used from the Phase 2 study assessing the efficacy and safety of olesoxime. A total of 110 individuals with Type 2 or 3 SMA were included in the analyses. Test-retest reliability (intraclass-correlation coefficient in global impression-defined stable individuals), internal consistency (Cronbach's alpha), convergent validity (Spearman rank order correlations with other measures), known-groups validity (analysis of covariance comparing Hammersmith Functional Motor Scale -defined groups), and ability to detect change (analysis of covariance comparing global impression-defined groups) were calculated. Strong evidence of test-retest reliability (intraclass-correlation coefficient = 0.93-0.95), internal consistency (Cronbach's alpha = 0.89), convergent validity (Hammersmith Functional Motor Scale: rho = 0.87; forced vital capacity: rho = 0.61), known-groups validity (all p<0.0001), and ability to detect change (all p<0.001) were demonstrated. These results provide evidence of the MFM32's measurement properties, supporting its use in longitudinal research in individuals with Type 2 and non-ambulant Type 3 SMA.

摘要

32 项运动功能测量(MFM32)是一种运动功能评估,其测量特性已在广泛的神经肌肉疾病人群中得到确立。本研究旨在调查 MFM32 在 2 型和非运动型 3 型脊髓性肌萎缩症(SMA)个体中的可靠性、有效性和检测变化的能力。数据来自评估奥索美龙疗效和安全性的 2 期研究。共有 110 名 2 型或 3 型 SMA 患者纳入分析。测试-重测可靠性(全球印象定义稳定个体的组内相关系数)、内部一致性(Cronbach's alpha)、收敛有效性(与其他测量的 Spearman 秩相关)、已知群体有效性(比较汉密尔顿运动功能量表定义组的协方差分析)和检测变化的能力(比较全球印象定义组的协方差分析)进行了计算。测试-重测可靠性(组内相关系数=0.93-0.95)、内部一致性(Cronbach's alpha=0.89)、收敛有效性(汉密尔顿运动功能量表:rho=0.87;用力肺活量:rho=0.61)、已知群体有效性(均<0.0001)和检测变化的能力(均<0.001)的证据均很强。这些结果提供了 MFM32 测量特性的证据,支持其在 2 型和非运动型 3 型 SMA 个体的纵向研究中使用。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验